AlphAIalphai — Financial news for AI agents
finance.yahoo.comAUG 22 min read$MYGN

Myriad Genetics (MYGN) Is Down 49.0% After Cutting 2026 Revenue Outlook Amid Prenatal Test Weakness

Simply Wall St reports Myriad Genetics (MYGN) shares are down 49% after the company cut its 2026 revenue outlook, citing weakness in prenatal testing. The piece references analyst fair value estimates and highlights potential positive and negative factors for investors, but provides no specific new financial figures beyond the outlook cut.

Original reporting
finance.yahoo.com
Published Aug 2, 2026, 5:09 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 2, 2026, 12:44 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Myriad Genetics (MYGN) Is Down 49.0% After Cutting 2026 Revenue Outlook Amid Prenatal Test Weakness — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$MYGNBearishLow
01

Why it matters

A revenue outlook cut tied to prenatal test weakness is typically a negative catalyst because it can reset forward estimates and increase uncertainty around growth and profitability.

02

Market read

Traders may focus on whether the prenatal test weakness is structural and how much of the 2026 outlook revision is recoverable.

03

What to watch

The body provides no details on whether the outlook cut reflects one-off issues (pricing, reimbursement, inventory) versus durable demand decline.

Relevance 4/10Novelty 2/10Timing: pre-market today (headline references a large drop and a 2026 outlook cut)

Background

The text is a Simply Wall St style promotional wrapper and does not provide the underlying guidance figures or operational drivers beyond the headline framing.

Company-level read

Ticker impact

$MYGNBearishLow confidence
Context

The article says Myriad Genetics cut its 2026 revenue outlook due to prenatal test weakness, driving a sharp selloff.

Expected impact

Bearish bias for the next several sessions as traders reprice 2026 revenue and related expectations.

Evidence & confidence

The provided body is mostly promotional boilerplate and does not include the specific guidance numbers or new details beyond the headline claim.

Market effects

Sector

Weak prenatal testing demand could weigh on sentiment for adjacent diagnostics and molecular testing names, but no peer-specific facts are provided.

Regional

No regional market linkage is described in the text.

Global

No global regulatory or competitive developments are mentioned.

Counterpoint

What could challenge this read

If the prenatal weakness is temporary (seasonality, mix shift, or channel digestion), the selloff could over-discount a faster normalization.

Key entities

  • company
    Myriad Genetics

    Subject of the article, referenced as cutting 2026 revenue outlook amid prenatal test weakness.

Read at source← All news

Related articles

AUG 1
$MYGNMedAI 8/10

Myriad Genetics Q2 Earnings Call Highlights

Myriad Genetics (MYGN) suspended adjusted EBITDA guidance due to uncertainty around initiatives. In Q2 it reported an adjusted EBITDA loss of $16.9M and adjusted loss per share of $0.25. Gross margin fell to 66.6% (66.6% excluding an $11M estimate impact: 68.4%). Liquidity was about $190M. Management cited worsening payer reimbursement friction and launched revenue-cycle and efficiency initiatives.

finance.yahoo.com6 min
JUL 31
$MYGNHighAI 9/10

Why Myriad Genetics (MYGN) Shares Are Falling Today

Myriad Genetics (MYGN) shares fell 46.1% after the company reported Q2 2026 results that missed Wall Street expectations and cut its full-year forecast. Revenue was $190.7 million, down 10.5% year over year, with an adjusted loss per share of $0.25. Full-year revenue guidance was reduced to a $780 million midpoint.

financialcontent.com4 min
JUL 30
$MYGNHighAI 9/10

Myriad Genetics (NASDAQ:MYGN) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops 28.6%

Genetic testing company Myriad Genetics (NASDAQ: MYGN) fell short of the market’s revenue expectations in Q2 CY2026, with sales falling 10.5% year on year to $190.7 million. The company’s full-year revenue guidance of $780 million at the midpoint came in 9.7% below analysts’ estimates. Its non-GAAP loss of $0.25 per share was significantly below analysts’ consensus estimates. Is now the time to buy Myriad Genetics? Find out by accessing our full research report, it’s free.

financialcontent.com4 min
JUL 30
$MYGNMed

MYRIAD GENETICS INC (MYGN): Results of Operations and Financial Condition

MYRIAD GENETICS INC (MYGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991mygn-xearningsrelease.htm EX-99.1 Document Exhibit 99.1 Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability Highl ights • Second quarter 2026 revenue of $190.

SEC EDGAR 8-K6 min
JUL 2
$MYGNMed

New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer

Myriad Genetics (NASDAQ: MYGN) said a meta-analysis of 14 studies (8,478 patients; individual data for 7,924) published in Clinical Genitourinary Cancer found its Prolaris biopsy test’s CCR score was prognostic for distant metastasis and prostate cancer-specific mortality across NCCN risk groups and management strategies, adding information beyond Gleason, CAPRA, and NCCN.

manilatimes.net3 min